A Novel MYH9-RET Fusion Occurrence and EGFR T790M Loss as an Acquired Resistance Mechanism to Osimertinib in a Patient with Lung Adenocarcinoma: A Case Report

Antzeko izenburuak

• A Novel MYH9-RET Fusion Occurrence and EGFR T790M Loss as an Acquired Resistance Mechanism to Osimertinib in a Patient with Lung Adenocarcinoma: A Case Report
  nork: Sun Y, et al.
  Argitaratua: (2020-11-01)
• Landscape of acquired resistance to osimertinib in EGFR-mutant NSCLC and clinical validation of combined EGFR and RET inhibition with osimertinib and BLU-667 for acquired RET fusion.
  nork: Piotrowska, Zofia, et al.
  Argitaratua: (2018)
• Acquired ALK and RET Gene Fusions as Mechanisms of Resistance to Osimertinib in EGFR-Mutant Lung Cancers
  nork: Offin, Michael, et al.
  Argitaratua: (2018)
• EGFR-mutated pulmonary adenocarcinoma with concurrent PIK3CA mutation, and with acquired RET fusion and EGFR T790M mutation after afatinib therapy
  nork: Kim, Minhye, et al.
  Argitaratua: (2021)
• EGFR L718Q mutation occurs without T790M mutation in a lung adenocarcinoma patient with acquired resistance to osimertinib
  nork: Ma, Lei, et al.
  Argitaratua: (2019)